Gossamer Bio, Inc.
GOSSHealthcare|Biotechnology|US
$9.77
+0.35 (+3.72%)
DCF Value
$117.58
Cash / Share
$20.66
Financials
Financial Snapshot
Market Cap
$59.7M
Enterprise Value
$57.7M
Revenue (TTM)
$53.3M
Net Income (TTM)
-$125.2M
Cash & Investments
$57.0M
Net Cash
$17.9M
Free Cash Flow (TTM)
-$162.6M
Operating CF (TTM)
-$162.6M
Debt/Equity
-0.42
Cash Runway & Burn Rate
Cash on Hand
$57.0M
Quarterly Burn
$40.7M
Monthly Burn
$13.6M
Est. Runway
~1.4 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $60.0K | $315.0K | $228.7M | $401.8M | $512.6M | $325.2M | $255.7M | $296.4M | $294.5M | $136.9M | $57.0M | |
| Operating Cash Flow | $20.0K | -$5.7M | -$51.0M | -$144.8M | -$176.4M | -$188.9M | -$187.0M | -$159.2M | -$3.5M | -$171.3M | -$162.6M | |
| Free Cash Flow | $20.0K | -$5.7M | -$72.3M | -$151.4M | -$201.2M | -$190.5M | -$187.5M | -$159.2M | -$3.5M | -$171.3M | -$162.6M | |
| Capital Expenditure | $0.00 | $0.00 | -$21.2M | -$6.6M | -$24.9M | -$1.6M | -$475.0K | $0.00 | $0.00 | -$79.0K | $0.00 | |
| Financing Cash Flow | $40.0K | $6.0M | $300.9M | $321.6M | $312.5M | $3.3M | $117.1M | $190.2M | -$11.5M | $6.4M | $3.2M |
R&D Spending
R&D (TTM)
$171.4M
R&D Intensity
321.7%
R&D Growth vs Prior
-1.5%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $114.7M | $48.5M | $53.3M | |
| R&D Expense | $0.00 | $891.0K | $55.3M | $143.4M | $158.0M | $170.3M | $170.9M | $135.3M | $138.5M | $174.1M | $171.4M | |
| R&D % of Revenue | — | — | — | — | — | — | — | — | 120.7% | 359.2% | 321.7% | |
| SG&A | $83.0K | $262.0K | $44.1M | $39.1M | $48.3M | $45.8M | $47.6M | $38.5M | $36.1M | $37.6M | $47.9M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $114.7M | $48.5M | $53.3M | |
| Cost of Revenue | $0.00 | $0.00 | $297.0K | $3.1M | $4.3M | $0.00 | $0.00 | $0.00 | $0.00 | $1.0M | $232.0K | |
| Gross Profit | $0.00 | $0.00 | -$297.0K | -$3.1M | -$4.3M | $0.00 | $0.00 | $0.00 | $114.7M | $47.5M | $53.1M | |
| R&D | $0.00 | $891.0K | $55.3M | $143.4M | $158.0M | $170.3M | $170.9M | $135.3M | $138.5M | $174.1M | $171.4M | |
| SG&A | $83.0K | $262.0K | $44.1M | $39.1M | $48.3M | $45.8M | $47.6M | $38.5M | $36.1M | $37.6M | $47.9M | |
| Operating Income | -$83.0K | -$6.7M | -$149.0M | -$186.1M | -$210.6M | -$216.1M | -$218.6M | -$183.8M | -$59.9M | -$163.3M | -$166.1M | |
| Interest Expense | $0.00 | $118.0K | $12.0K | $0.00 | $12.7M | $19.4M | $13.9M | $13.5M | $11.5M | $11.0M | $11.0M | |
| Pretax Income | -$83.0K | -$6.8M | -$147.0M | -$180.3M | -$243.4M | -$234.0M | -$229.4M | -$179.8M | -$55.6M | -$170.5M | -$125.3M | |
| Net Income | -$83.0K | -$6.8M | -$147.0M | -$180.8M | -$243.4M | -$234.0M | -$229.4M | -$179.8M | -$56.5M | -$170.4M | -$125.2M | |
| EPS (Diluted) | -0.72 | -59.13 | -1807.49 | -263.51 | -284.17 | -250.13 | -216.97 | -94.26 | -19.99 | -59.64 | -55.66 | |
| EBITDA | $0.00 | -$5.5M | -$149.0M | -$179.4M | -$226.4M | -$209.4M | -$211.1M | -$161.9M | -$40.0M | -$158.5M | -$204.5M | |
| Shares Out. (M) | 0.11 | 0.11 | 0.08 | 0.68 | 0.86 | 0.94 | 1.06 | 1.91 | 2.83 | 2.86 | 4.11 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $60.0K | $315.0K | $105.2M | $135.0M | $486.1M | $183.4M | $112.0M | $32.1M | $46.1M | $37.7M | $41.1M | |
| Short-Term Investments | $0.00 | $0.00 | $123.4M | $266.7M | $26.6M | $141.8M | $143.7M | $264.3M | $248.4M | $99.2M | $15.9M | |
| Total Current Assets | $60.0K | $445.0K | $232.0M | $409.3M | $522.3M | $331.8M | $261.9M | $306.5M | $309.9M | $167.6M | $72.7M | |
| Total Assets | $60.0K | $445.0K | $239.4M | $426.6M | $539.4M | $343.7M | $272.4M | $311.9M | $315.3M | $172.2M | $76.9M | |
| Total Current Liabilities | $143.0K | $1.3M | $20.4M | $36.9M | $38.6M | $39.9M | $49.2M | $51.6M | $45.0M | $63.4M | $137.8M | |
| Long-Term Debt | $40.0K | $6.0M | $0.00 | $28.5M | $172.4M | $179.1M | $207.7M | $197.4M | $197.5M | $198.5M | $0.00 | |
| Total Liabilities | $183.0K | $7.3M | $359.5M | $74.1M | $218.7M | $222.2M | $260.4M | $249.1M | $285.8M | $295.0M | $170.9M | |
| Stockholders' Equity | -$123.0K | -$6.9M | -$120.1M | $352.5M | $320.7M | $121.5M | $12.1M | $62.8M | $29.5M | -$122.8M | -$94.0M | |
| Retained Earnings | -$123.0K | -$6.9M | -$153.9M | -$334.2M | -$577.5M | -$811.5M | -$1.03B | -$1.21B | -$1.27B | -$1.44B | -$1.47B |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $20.0K | -$5.7M | -$51.0M | -$144.8M | -$176.4M | -$188.9M | -$187.0M | -$159.2M | -$3.5M | -$171.3M | -$162.6M | |
| Capital Expenditure | $0.00 | $0.00 | -$21.2M | -$6.6M | -$24.9M | -$1.6M | -$475.0K | $0.00 | $0.00 | -$79.0K | $0.00 | |
| Free Cash Flow | $20.0K | -$5.7M | -$72.3M | -$151.4M | -$201.2M | -$190.5M | -$187.5M | -$159.2M | -$3.5M | -$171.3M | -$162.6M | |
| Investing Cash Flow | $0.00 | $0.00 | -$144.7M | -$147.1M | $215.3M | -$117.4M | -$1.0M | -$111.0M | $29.0M | $156.4M | $174.5M | |
| Financing Cash Flow | $40.0K | $6.0M | $300.9M | $321.6M | $312.5M | $3.3M | $117.1M | $190.2M | -$11.5M | $6.4M | $3.2M | |
| Issuance of Stock | $0.00 | $0.00 | $229.6M | $291.3M | $117.1M | $0.00 | $119.9M | $201.3M | $464.0K | $6.4M | $6.3M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $629.0K | $0.00 | $0.00 | |
| Net Debt Issuance | $40.0K | $6.0M | -$40.0K | $28.2M | $193.6M | $0.00 | -$5.8M | -$11.6M | -$12.6M | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $32.0K | $30.9M | $20.8M | $38.7M | $32.0M | $42.6M | $28.5M | $20.6M | $10.6M | $14.3M | |
| Net Change in Cash | $0.00 | $255.0K | $105.1M | $29.7M | $351.5M | -$303.2M | -$71.5M | -$79.9M | $14.0M | -$8.3M | $14.8M |
Dilution Tracker
Shares outstanding grew 233.6% over 5 years — significant dilution
Shares Outstanding
6M
5-Year Share Growth
+233.6%
Stock Issuance (TTM)
$6.3M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.11 | 0.11 | 0.08 | 0.68 | 0.86 | 0.94 | 1.06 | 1.91 | 2.83 | 2.86 | 4.11 | |
| Change vs Prior % | — | 0.0% | -29.0% | 741.5% | 25.2% | 9.2% | 13.0% | 80.5% | 48.2% | 1.0% | 43.9% | |
| Stock Issuance | $0.00 | $0.00 | $229.6M | $291.3M | $117.1M | $0.00 | $119.9M | $201.3M | $464.0K | $6.4M | $6.3M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $629.0K | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $32.0K | $30.9M | $20.8M | $38.7M | $32.0M | $42.6M | $28.5M | $20.6M | $10.6M | $14.3M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | — | — | — | — | — | — | — | — | 100.0% | 97.9% | 99.6% | |
| Operating Margin % | — | — | — | — | — | — | — | — | -52.2% | -336.8% | -311.7% | |
| Net Margin % | — | — | — | — | — | — | — | — | -49.3% | -351.5% | -235.0% | |
| EBITDA Margin % | — | — | — | — | — | — | — | — | -34.8% | -326.9% | -383.8% | |
| FCF Margin % | — | — | — | — | — | — | — | — | -3.0% | -353.5% | -305.2% | |
| ROE % | 67.5% | 98.7% | 122.4% | -51.3% | -75.9% | -192.7% | -1899.3% | -286.5% | -191.7% | 138.8% | 108.7% | |
| ROA % | -138.3% | -1521.6% | -61.4% | -42.4% | -45.1% | -68.1% | -84.2% | -57.6% | -17.9% | -98.9% | -162.9% | |
| ROIC % | 100.0% | 810.4% | -68.0% | -47.5% | -41.7% | -70.5% | -91.9% | -66.8% | -22.1% | -148.7% | 670.0% | |
| R&D / Revenue % | — | — | — | — | — | — | — | — | 120.7% | 359.2% | 321.7% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -57.7% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | -940.1% | -38.2% | 100.0% | 0.0% | 0.0% | 0.0% | -58.6% | |
| Operating Income | 0.0% | -7915.7% | -2139.5% | -24.9% | -13.1% | -2.6% | -1.1% | 15.9% | 67.4% | -172.5% | |
| Net Income | 0.0% | -8057.8% | -2070.6% | -23.0% | -34.6% | 3.8% | 2.0% | 21.6% | 68.6% | -201.4% | |
| EPS (Diluted) | 0.0% | -8112.5% | -2956.8% | 85.4% | -7.8% | 12.0% | 13.3% | 56.6% | 78.8% | -198.3% | |
| Operating Cash Flow | 0.0% | -28825.0% | -788.5% | -183.7% | -21.8% | -7.1% | 1.0% | 14.9% | 97.8% | -4838.5% | |
| Free Cash Flow | 0.0% | -28825.0% | -1157.7% | -109.5% | -32.9% | 5.3% | 1.6% | 15.1% | 97.8% | -4840.7% | |
| R&D Expense | 0.0% | 0.0% | 6104.6% | 159.4% | 10.2% | 7.8% | 0.4% | -20.8% | 2.4% | 25.7% | |
| SG&A Expense | 0.0% | 215.7% | 16713.4% | -11.2% | 23.5% | -5.3% | 4.0% | -19.2% | -6.0% | 4.1% | |
| Total Assets | 0.0% | 641.7% | 53702.0% | 78.2% | 26.4% | -36.3% | -20.7% | 14.5% | 1.1% | -45.4% | |
| Book Value / Share | 0.0% | -5478.9% | -2364.2% | 134.9% | -27.3% | -65.3% | -91.2% | 188.0% | -68.3% | -512.1% | |
| Debt | 0.0% | 15000.0% | -100.0% | 0.0% | 364.6% | 0.8% | 21.9% | -5.9% | -4.5% | 0.0% | |
| Diluted Shares | 0.0% | 0.0% | -29.0% | 741.5% | 25.2% | 9.2% | 13.0% | 80.5% | 48.2% | 1.0% |
Valuation
P/E (TTM)At Loss
P/S1.12
P/B-0.29
10Y Low / Med / High2.07 / 6.94 / 15.20
EV/EBITDAAt Loss
EV/Revenue1.08
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$117.58
Cash / Share
$20.66
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -1993.33 | -24.27 | -0.79 | -4.75 | -2.72 | -3.62 | -0.80 | -0.77 | -3.62 | -4.16 | -0.22 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.78 | 14.62 | 1.12 | |
| P/B Ratio | -1336.15 | -23.95 | -0.97 | 2.43 | 2.07 | 6.97 | 15.20 | 2.22 | 6.94 | -5.77 | -0.29 | |
| EV/EBITDA | 0.00 | -30.92 | -0.08 | -4.24 | -1.59 | -4.05 | -1.41 | -1.97 | -9.04 | -5.51 | -0.28 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.15 | 18.02 | 1.08 |
Analyst Estimates & Quality
Altman Z-Score
-35.68
Distress
Piotroski F-Score
3
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $40.5M | $16.7M | $64.3M |
| Net Income | -$53.4M | -$31.3M | -$49.1M |
| EPS | $-15.62 | $-10.52 | $-9.60 |
| # Analysts (EPS) | 4 | 4 | 5 |
Revenue Segments
By Product
| Segment | 2024 | 2025 |
|---|---|---|
| License and Service | $90.7M | — |